Search This Blog

Thursday, July 4, 2019

FDA accepts Insys’ NDA for naloxone nasal spray for opioid overdose

The FDA has accepted Insys Therapeutics’ (NASDAQ:INSY) NDA for its investigational, naloxone nasal spray for the emergency treatment of opioid overdose in both adult and pediatric patients.
A single unit dose spray device delivers 8mg naloxone dose.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)